CEQUA SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CYCLOSPORINE

Предлага се от:

SUN PHARMACEUTICAL INDUSTRIES LIMITED

АТС код:

S01XA18

INN (Международно Name):

CICLOSPORIN

дозиране:

0.09%

Лекарствена форма:

SOLUTION

Композиция:

CYCLOSPORINE 0.09%

Начин на приложение:

OPHTHALMIC

Броя в опаковка:

15G/50G

Вид предписание :

Prescription

Каталог на резюме:

Active ingredient group (AIG) number: 0115996010; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2022-01-10

Данни за продукта

_CEQUA™ Product Monograph _
_Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
CEQUA™
Cyclosporine Ophthalmic Solution
Solution, 0.09% w/v
Anti-Inflammatory / Immunomodulator
Pharmacotherapeutic group: Ophthalmologicals, other ophthalmologicals,
ATC code: S01XA18
Sun Pharmaceutical Industries Ltd.
Sun House, Plot 201 B/1
Western Express Highway, Goregaon (E)
Mumbai - 400 063
Maharashtra, India
Imported and Distributed by:
Sun Pharma Canada Inc.
Brampton, Ontario
L6T 1C1
Date of Initial Approval:
February 15, 2021
Date of Revision:
January 5, 2022
Submission Control No.: 259168
CEQUA
™
is a trademark of Sun Pharmaceutical Industries Ltd.
_ _
_CEQUA™ Product Monograph _
_Page 2 of 21_
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................2
1
INDICATIONS
....................................................................................................................4
1.1
Pediatrics
....................................................................................................................4
1.2
Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................4
3
DOSAGE AND ADMINISTRATION ...............................................................................4
3.1
Dosing Considerations
...............................................................................................4
3.2
Recommended Dose and Dosage Adjustment
...........................................................4
3.3
Administration
...........................................................................................................5
3.4
Missed Dose
...............................................................................................................5
4
OVERDOSAGE .................................................